FibroBiologics (FBLG) announced the filing of a patent application with the United States Patent and Trademark Office covering methods employing fibroblasts or other Tissue Factor-expressing cells to ...
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the ...
After an allogeneic stem cell transplant, a recipient’s body faces a daunting task: rebuilding the person’s blood-forming and immune systems from the ground up from a relatively small number of “seed” ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Every year, tens of thousands of people in the U.S. undergo ...
A new study shows that giving the chemotherapy drug cyclophosphamide after allogeneic hematopoietic cell transplantation, a curative treatment for common types of blood cancer, can make the procedure ...
In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received ...
Stem cell transplants remain essential for blood cancers, with expanded donor options including half-matched family members and umbilical cord blood. Cyclophosphamide has improved graft-versus-host ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback